Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
September 15, 2003
- METI Wants \3 Bil. to Support Health Services Industry
September 15, 2003
- NEW PRODUCTS
September 15, 2003
- Korosho to Submit Bill for "Basic Pharmaceutical Research Institute"
September 15, 2003
- Financial Results in 1st Quarter
September 15, 2003
- Healthcare Associations to Survey Lawmakers on Social Security
September 15, 2003
- Revised Hypertension GL to Include Major Changes in Drug Therapy: Dr Saruta
September 15, 2003
- REGULATORY NEWS IN BRIEF
September 15, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 15, 2003
- Kyowa Hakko Steps Up Patient Education Activities for Nocturnal Enuresis
September 15, 2003
- OTC NEWS IN BRIEF
September 15, 2003
- Fujisawa Establishes Centralized Drug Info Collection System
September 15, 2003
- DIAGNOSTIC NEWS IN BRIEF
September 15, 2003
- Sankyo Licenses Olmesartan to Pfizer
September 15, 2003
- MEDICAL DEVICE NEWS IN BRIEF
September 15, 2003
- Asahi Kasei Pharma to Specialize in Brain/CNS, Urology, Bones
September 8, 2003
- Takara Bio Succeeds in Enhancing Production of Activated Lymphocytes
September 8, 2003
- CROs Prefer Experienced People Over New Grads: Survey
September 8, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
September 8, 2003
- BUSINESS NEWS IN BRIEF
September 8, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…